These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28274247)

  • 1. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
    Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
    Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
    Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
    Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
    Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.
    Ma J; Xue Y; Cui W; Li Y; Zhao Q; Ye W; Zheng J; Cheng Y; Ma Y; Li S; Han T; Miao L; Yao L; Zhang J; Liu W
    Cancer; 2012 Sep; 118(17):4105-16. PubMed ID: 22907703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
    Pang X; Wu Y; Wu Y; Lu B; Chen J; Wang J; Yi Z; Qu W; Liu M
    Mol Cancer Ther; 2011 May; 10(5):795-805. PubMed ID: 21372225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
    Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
    Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo.
    Niu X; Li S; Wei F; Huang J; Wu G; Xu L; Xu D; Wang S
    Breast Cancer; 2014 Mar; 21(2):223-30. PubMed ID: 22711315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
    Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
    Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
    Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
    Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
    Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
    Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival.
    Liu T; Zhang H; Xiong J; Yi S; Gu L; Zhou M
    Mol Cancer; 2015 Mar; 14():65. PubMed ID: 25888903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.